Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10. 9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio.
Source: [Bloomberg Markets](https://www.bloomberg.com/news/videos/2026-06-22/abbvie-to-buy-apogee-therapeutics-for-10-9-billion-video)